Understanding who enforces medicines regulations in the EU is the real clinical trial - side effects include confusion and legal headaches.<\/pre>\n\n\n\nImagine a pharmaceutical company fails to report a serious side effect. A national authority might detect the issue, the European Medicines Agency (EMA)<\/a> would investigate it, but the final decision on penalties would be taken elsewhere. Because the responsibility is divided between different institutions, it becomes unclear who is actually accountable.<\/p>\n
This post explores why, despite detailed rules and strong institutions, responsibility in EU pharmaceutical enforcement can become so fragmented that no single actor is clearly accountable.<\/p>\n
The EU pharmaceutical regulation is built on a comprehensive legal framework. Directive <\/a>2001\/83\/EC<\/a> sets out the general rules for medical products. For authorised medicines distributed within the EU, Regulation (EC) <\/a>No 726\/2004<\/a> establishes EMA\u2019s role and powers. Furthermore, instruments such as the Clinical Trials Regulation<\/a> and<\/a> strengthened pharmacovigilance rules<\/a> further strengthen and monitor safety obligations across the EU. The framework is extensive. However, the way the rules are applied determines whether they actually matter.<\/p>\n
Pharmacovigilance rules<\/strong>
Legal requirements and guidelines ensure that medicines are monitored for safety, so their benefits outweigh their risks.<\/pre>\n\n\n\nHere is where things get complicated. In practice, enforcement is divided between different actors, each with a specific role:<\/p>\n
\n
- National authorities detect problems<\/a> at the Member State level<\/a><\/li>\n
- The EMA investigates and assesses<\/a> possible violations<\/a><\/li>\n
- The European Commission decides whether to impose fines<\/a><\/li>\n<\/ul>\n
This means that while EMA plays a central role in supervision and investigation, it cannot impose fines. Even though the financial penalties can reach up to 5% of a company\u2019s EU turnover for certain infringements<\/a>, the power to impose the fines rests with the Commission. This creates a gap between the investigation and the ensuring of compliance. When enforcement <\/a>is shared<\/a>, establishing accountability becomes more difficult.<\/p>\n
Comparative perspective<\/strong><\/p>\n
By contrast, other EU agencies such as the European Securities and Markets Authority (ESMA) <\/a>and the European Central Bank (ECB)<\/a> have the power to investigate violations and impose fines directly. Therefore, the EMA model stands in contrast. For example, ESMA can directly supervise specific market actors, adopt binding decisions, including financial penalties, without relying on another EU institution. Similarly, the ECB supervises banks and imposes sanctions for breaches of EU banking rules.<\/p>\n
These differences in enforcement powers become clearer when we look at how the system operates in practice.<\/p>\n
How Enforcement Works in Practice<\/strong><\/p>\n
Four years, nineteen medicines, zero fines<\/strong><\/p>\n
The only infringement procedure ever opened under EU pharmaceutical law tells us less about wrongdoing than about how the system divides authority.<\/pre>\n\n\n\n
![\"\"](\"https:\/\/eulawenforcement.com\/wp-content\/uploads\/2026\/04\/image-16.png\")
![\"\"](\"https:\/\/eulawenforcement.com\/wp-content\/uploads\/2026\/04\/image-17.png\")
![\"\"](\"https:\/\/eulawenforcement.com\/wp-content\/uploads\/2026\/04\/original-F44104F5-18C7-4116-9BCA-40680DD11D8D-1030x1107.jpeg\")